Bionote "Enters the global market with POCT PCR device M10"

DISCLAIMER: This news article is a direct translation of the original Korean article from eDaily. BioNote Inc. does not claim any right to the article or claim any ownership.

The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.



[E-Daily Reporter Seok Ji-heon] Bionote, a global leading company in bio content and animal diagnosis, announced on the 2nd that the " state-of-the-art field molecular diagnostic equipment Vcheck M10 (hereinafter, M10)", which was recently introduced in overseas markets. M10 received favorable reviews at the 2022 World Small Animal Veterinary Association (WSAVA). The event was held in Lima, Peru from the 29th to the 31st of last month. 


"We once again confirmed the possibility of success in the global market due to the M10 products' innovative technology," a Bionote official said. "Bionote, which has previously shown expertise in immunodiagnosis, will become a global leader in providing total solutions from initial screening to PCR confirmation."

M10 is an automated device that integrates nucleic acid extraction and nucleic acid amplification (PCR) into one device, which was previously carried out by separate equipments. M10 has a very simple inspection process, so using this equipment, veterinarians at general veterinary hospitals can conduct PCR tests at animal hospitals without additional training. The company explained that this is groundbreaking because it can quickly and accurately perform PCR confirmation tests at the field in an hour, which was requested by a professional inspection agency, which took about 1 to 3 days.

M10 equipment has completed the export license of the quarantine headquarters and the European CE certification, and is preparing for domestic use. As a cartridge used in M10 equipment, "Vcheck MEhrlichia/Anaplasma" was launched overseas for the first time in September this year, and "Vcheck M Babesia gibsoni/canis" was developed as the second item and is being prepared for overseas launch in November. Cartridges that can test up to eight types of animal diseases at a time will also be introduced within this year.

Meanwhile, Bionote is seeking to be listed on the KOSPI within this year to accelerate global growth.